Download presentation
Presentation is loading. Please wait.
Published byLetitia Washington Modified over 9 years ago
1
Examples of systematic reviews Goran Poropat
2
Cochrane systematic reviews To make unmanageable amounts of information – manageable Identify, appraise and synthesize research-based evidence Present in an accessible format
3
Cochrane systematic reviews Clearly stated set of objectives Explicit, reproducible methodology Systematic search Assessment of validity Systematic presentation
5
Protocol for a Cochrane review Idea Register title Write protocol To minimize the potential for bias in the review process Changes possible
6
Bezafibrate for primary biliary cirrhosis Title* Protocol information: Authors* Contact person* Dates What’s new History The protocol: Background* Objectives* Methods: Criteria for selecting studies for this review: Types of studies* Types of participants* Types of interventions* Types of outcome measures* Search methods for identification of studies* Data collection and analysis* Acknowledgements References: Other references: Additional references Other published versions of this review Tables and figures: Additional tables Figures Supplementary information: Appendices Feedback: Title Summary Reply Contributors About the article: Contributions of authors Declarations of interest* Sources of support: Internal sources External sources Published notes
7
Bezafibrate for primary biliary cirrhosis
8
Chronic, progressive, inflammatory and autoimmune- mediated liver disease Survival in symptomatic patients = 10-15 yr. Bilirubin – indipendent predictor of survival and prognosis Bezafibrate – inhibition of acetil-CoA carboxylase activity PPAR - ATP-binding cassette (ABC) B4 transporter Increased secretion of phosphatidyl-choline
9
Bezafibrate for primary biliary cirrhosis Methods Types of studies RCTs assessing bezafibrate in patients with PBC Irrespective of blinding, language, publication status Quasi-randomised and observational studies – Exluded for report of benefit – Included for report of harm
10
Bezafibrate for primary biliary cirrhosis Types of participants Pts with PBC – Elevated alkaline phophatases – Positive anti-mitochondrial antibody – Compatible liver biopsy Types of interventions – bezafibrate at any dose or regimen vs. placebo or any other drug
11
Bezafibrate for primary biliary cirrhosis Types of outcome measures
12
Bezafibrate for primary biliary cirrhosis Search methods of identification of studies Cochrane Hepato-Biliary Group Controlled Trials Register The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library MEDLINE EMBASE Science Citation Index Expanded LILACS Chinese Bio-medical Literature Database Reference lists of identified studies Pharmaceutical companies Clinicaltrials.gov WHO International Clinical Trials Registry Platform
13
Bezafibrate for primary biliary cirrhosis Data collection and analysis Two authors independently Disagreements resolved by discussion Risk of bias assessment Allocation sequence generation Allocation concealment Blinding Incomplete outcome data Selective outcome reporting Other bias
14
Bezafibrate for primary biliary cirrhosis Statistical analyses Fixed-effect and random-effect models meta-analyses Dichotomous outcomes – RR/RD (95% CI) Continuous outcomes – MD (95% CI) Dichotomous outcomes – intention-to-treat Continuous outcomes – case analysis and inclusion of known data Assesment of heterogeneity (chi-square test) Trial sequential analysis
15
Search results 91 PUBLICATIONS IDENTIFIED 65 PUBLICATIONS ASSESSED 7 PUBLICATIONS INCLUDED 6 TRIALS INCLUDED 26 DUPLICATES 58 PUBLICATIONS EXCLUDED 4 TRIALS (N=82) Bezafibrate vs. no intervention 2 TRIALS (N=69) Bezafibrate vs. UDCA
16
Characteristics of included studies All trials from Japan Parallel groups design (5 trials) Cross-over design (1 trial) >85% participants were female Non-advanced PBC (4 trials) PBC stage not known (2 trials)
17
Characteristics of included studies Bezafibrate 400 mg daily orally Duration of administration of bezafibrate – 6 moths (2 trials) – 12-13 months (4 trials) UDCA 600 mg daily orally
18
Risk of bias judgement All six trials are at high risk of bias
19
Results: Trials assessing bezafibrate vs. no intervention
20
LIVER-RELATED MORBIDITY ALL-CAUSE MORTALITY
21
PRURITUS ADVERSE EVENTS
22
ALKALINE PHOSPHATASES MD -186, 95% CI -249 to -123; I 2 = 34%
23
Trial sequential analysis (ALP) A minimal relevant difference100 U/L (based on clinical judgement, more modest than the estimated effect seen in the meta-analysis) Standard deviation 200 U/L Risk of type I error5% Risk of type II error20% Required information size216
24
TSA – ALKALINE PHOSPHATASES
25
Other results IgM Bilirubin GT ALT Total cholesterol Tryglicerids No effect on
26
Conclusion Bezafibrate vs. no intervention No significant effect on mortality, liver-related morbidity, adverse events, and pruritus Quality of life and fatigue could not be assessed Trial sequential analysis implies evidence for a beneficial effect on serum alkaline phosphatases activity
27
Results: Trials assessing bezafibrate vs. ursodeoxycholic acid (UDCA)
28
LIVER-RELATED MORBIDITY ALL-CAUSE MORTALITY
29
ALKALINE PHOSPHATASES ADVERSE EVENTS
30
Other results Fixed-effect analysis Random-effect analysis Significant decrease of ALP, GT, ALT, IgM No effect on GT, ALT, IgM
31
Conclusion Bezafibrate vs. UDCA No significant effect on mortality, liver-related morbidity, adverse events, and pruritus Quality of life, pruritus, and fatigue could not be assessed There is no firm evidence of effect on ALP, GT, ALT, and IgM
32
CONCLUSIONS Treatment of primary biliary cirrhosis with bezafibrate can neither be supported nor rejected
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.